Clinical trial
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid…
NCT00117013 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00117013 |
|---|---|
| Title | A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a |
| Official title | A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Fluorine-19-Fluoroded Xyglucose, Topotecan |
| Enrollment | 16 |
| Start date | Jun 28, 2005 |
| Primary completion | Oct 25, 2010 |
| Completion | Oct 25, 2010 |
| First posted | Jul 1, 2005 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: